Terms: = Lung cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Clinical Outcome
124 results:
1. A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Guo H; Li Y; Lin J; Li D; Yang J; Wang J; Mao J; Wang Y; Yan X
Int Immunopharmacol; 2024 Mar; 129():111611. PubMed ID: 38325047
[TBL] [Abstract] [Full Text] [Related]
2. Whole stromal fibroblast signature is linked to specific chemokine and immune infiltration patterns and to improved survival in NSCLC.
Koeck S; Amann A; Kern J; Zwierzina M; Lorenz E; Sopper S; Zwierzina H; Mildner F; Sykora M; Sprung S; Hackl H; Augustin F; Maier HT; Pircher A; Pall G; Wolf D; Gamerith G
Oncoimmunology; 2023; 12(1):2274130. PubMed ID: 38126028
[TBL] [Abstract] [Full Text] [Related]
3. A Nasal Swab Classifier to Evaluate the Probability of lung cancer in Patients With Pulmonary Nodules.
Lamb CR; Rieger-Christ KM; Reddy C; Huang J; Ding J; Johnson M; Walsh PS; Bulman WA; Lofaro LR; Wahidi MM; Feller-Kopman DJ; Spira A; Kennedy GC; Mazzone PJ
Chest; 2024 Apr; 165(4):1009-1019. PubMed ID: 38030063
[TBL] [Abstract] [Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
5. Differentiating interstitial lung diseases from other respiratory diseases using electronic nose technology.
van der Sar IG; Wijsenbeek MS; Braunstahl GJ; Loekabino JO; Dingemans AC; In 't Veen JCCM; Moor CC
Respir Res; 2023 Nov; 24(1):271. PubMed ID: 37932795
[TBL] [Abstract] [Full Text] [Related]
6. Characterization of the pleural microenvironment niche and cancer transition using single-cell RNA sequencing in EGFR-mutated lung cancer.
Wu YY; Hsu YL; Huang YC; Su YC; Wu KL; Chang CY; Ong CT; Lai JC; Shen TY; Lee TH; Hung JY; Tsai YM
Theranostics; 2023; 13(13):4412-4429. PubMed ID: 37649596
[No Abstract] [Full Text] [Related]
7. Glycolysis induces Th2 cell infiltration and significantly affects prognosis and immunotherapy response to lung adenocarcinoma.
Zeng L; Liang L; Fang X; Xiang S; Dai C; Zheng T; Li T; Feng Z
Funct Integr Genomics; 2023 Jul; 23(3):221. PubMed ID: 37400733
[TBL] [Abstract] [Full Text] [Related]
8. POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Li Y; Yang Q; Liu Y; Yi H; Ju Y; Qi G
Invest New Drugs; 2023 Aug; 41(4):556-563. PubMed ID: 37318657
[TBL] [Abstract] [Full Text] [Related]
9. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gravis G; Marino P; Olive D; Penault-LLorca F; Delord JP; Simon C; Lamrani-Ghaouti A; Sabatier R; Ciccolini J; Boher JM
BMC Cancer; 2023 May; 23(1):393. PubMed ID: 37131154
[TBL] [Abstract] [Full Text] [Related]
10. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
[TBL] [Abstract] [Full Text] [Related]
11. Acute Influenza Infection Promotes lung Tumor Growth by Reprogramming the Tumor Microenvironment.
Garmendia I; Varthaman A; Marmier S; Angrini M; Matchoua I; Darbois-Delahousse A; Josseaume N; Foy PE; Roumenina LT; Naouar N; Meylan M; Sibéril S; Russick J; Joubert PE; Leroy K; Damotte D; Mansuet-Lupo A; Wislez M; Alifano M; Menger L; Garcia-Verdugo I; Sallenave JM; Lantz O; Petitprez F; Cremer I
Cancer Immunol Res; 2023 Apr; 11(4):530-545. PubMed ID: 36883368
[TBL] [Abstract] [Full Text] [Related]
12. Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data.
So WV; Dejardin D; Rossmann E; Charo J
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822668
[TBL] [Abstract] [Full Text] [Related]
13. Model selection for survival individualized treatment rules using the jackknife estimator.
Honvoh GD; Cho H; Kosorok MR
BMC Med Res Methodol; 2022 Dec; 22(1):328. PubMed ID: 36550398
[TBL] [Abstract] [Full Text] [Related]
14. Guidelines on lung adenocarcinoma prognosis based on immuno-glycolysis-related genes.
Zhang Y; Qin W; Zhang W; Qin Y; Zhou YL
Clin Transl Oncol; 2023 Apr; 25(4):959-975. PubMed ID: 36447119
[TBL] [Abstract] [Full Text] [Related]
15. A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts clinical Prognosis and Demonstrates Immune Relevancy in lung Adenocarcinoma.
Huang X; Lu Z; He M; Feng Y; Yu S; Shen B; Lu J; Wu P; Pan B; Ding H; Chen C; Sun Y
Oxid Med Cell Longev; 2022; 2022():2262014. PubMed ID: 36439693
[TBL] [Abstract] [Full Text] [Related]
16. Artificial Intelligence in Breast cancer Screening: Evaluation of FDA Device Regulation and Future Recommendations.
Potnis KC; Ross JS; Aneja S; Gross CP; Richman IB
JAMA Intern Med; 2022 Dec; 182(12):1306-1312. PubMed ID: 36342705
[TBL] [Abstract] [Full Text] [Related]
17. DNA Methylation Profiling Identifies Subgroups of lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and clinical outcome.
Guidry K; Vasudevaraja V; Labbe K; Mohamed H; Serrano J; Guidry BW; DeLorenzo M; Zhang H; Deng J; Sahu S; Almonte C; Moreira AL; Tsirigos A; Papagiannakopoulos T; Pass H; Snuderl M; Wong KK
Clin Cancer Res; 2022 Sep; 28(17):3824-3835. PubMed ID: 35802677
[TBL] [Abstract] [Full Text] [Related]
18. Dynamic Changes of Circulating Tumor DNA Predict clinical outcome in Patients With Advanced Non-Small-Cell lung cancer Treated With Immune Checkpoint Inhibitors.
Weber S; van der Leest P; Donker HC; Schlange T; Timens W; Tamminga M; Hasenleithner SO; Graf R; Moser T; Spiegl B; Yaspo ML; Terstappen LWMM; Sidorenkov G; Hiltermann TJN; Speicher MR; Schuuring E; Heitzer E; Groen HJM
JCO Precis Oncol; 2021 Nov; 5():1540-1553. PubMed ID: 34994642
[TBL] [Abstract] [Full Text] [Related]
19. Identification of seven-gene marker to predict the survival of patients with lung adenocarcinoma using integrated multi-omics data analysis.
Zhang S; Zeng X; Lin S; Liang M; Huang H
J Clin Lab Anal; 2022 Feb; 36(2):e24190. PubMed ID: 34951053
[TBL] [Abstract] [Full Text] [Related]
20. Overall Survival Prognostic Modelling of Non-small Cell lung cancer Patients Using Positron Emission Tomography/Computed Tomography Harmonised Radiomics Features: The Quest for the Optimal Machine Learning Algorithm.
Amini M; Hajianfar G; Hadadi Avval A; Nazari M; Deevband MR; Oveisi M; Shiri I; Zaidi H
Clin Oncol (R Coll Radiol); 2022 Feb; 34(2):114-127. PubMed ID: 34872823
[TBL] [Abstract] [Full Text] [Related]
[Next]
